The Drug Enforcement Administration Friday proposed limiting telehealth prescriptions for buprenorphine and other controlled substances after the COVID-19 public health emergency to a 30-day supply unless the prescriber or referring clinician have evaluated the patient in person. DEA will accept comments on the proposed rules for 30 days after their publication in the Federal Register. The Biden Administration last month said it plans to end the COVID-19 national and public health emergencies on May 11. 

AHA has urged the DEA to propose a special registration process for prescribing medically necessary controlled substances via telehealth after the COVID-19 PHE; provide an interim plan to support continuity of care if the PHE expires before the rules are finalized; and grant a permanent exception for separate registrations for practitioners in states that have medical licensing reciprocity requirements.

According to a recent federal study, the share of U.S. overdose deaths involving buprenorphine did not increase after federal agencies allowed clinicians to prescribe the opioid use disorder treatment remotely during the COVID-19 PHE. 

AHA members will receive a Special Bulletin with more on the proposed rules once DEA publishes them in the Federal Register.
 

Related News Articles

Headline
The Occupational Safety and Health Administration today announced a 60-day extension of the comment period on its proposed rule to remove the remaining…
Headline
COVID-19 infections are growing or likely growing in 45 states and not changing in five states, according to the latest data from the Centers for Disease…
Chairperson's File
Public
The recently enacted One Big Beautiful Bill Act will bring big changes to health care. AHA President and CEO Rick Pollack joined me for a Leadership Dialogue…
Headline
The Food and Drug Administration July 15 announced a recall by Sandoz on certain lots of cefazolin, due to the lots being mislabeled as penicillin G potassium…
Headline
 The Food and Drug Administration July 10 approved Moderna’s Spikevax COVID-19 vaccine for children under 12 with at least one underlying condition that…
Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…